Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma

Slides:

Advertisements

Similar presentations

Our bold approach to life-changing medicines

Advertisements

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

Clinical Cancer Advances 2010 ASCO’s Annual Report on Progress Against Cancer.

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.

Multimodal Management of Opioid-Induced Constipation

The Nurse’s Role in Inflammatory Bowel Disease

The Nurse View: Management of Pancreatic Cancer

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.

Clinical tips and pearls

Familial Chylomicronemia Syndrome

The Nurse View.

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Perspectives on Triple-Negative Breast Cancer

Starting Strong: Initial Evaluation of the Patient With HCV

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Tailoring Statin Therapy in Women

Updates in Hodgkin Lymphoma

Progression After Cancer Immunotherapy in Advanced NSCLC

Patient 1: 53-Year-Old Man With CVD Risk Factors

Addressing Neuropsychiatric Symptoms in Patients With Dementia

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Complicated Cases in Ulcerative Colitis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.

A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.

Checkpoint Inhibition

Best Practices in Metastatic Colorectal Cancer

Team-Based Perspectives on Successful Approaches in Treating Obesity

More Than Meets the Eye.

The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.

From Symptom Management to Communication in Advanced GI Cancers

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Opportunities and Challenges in the Management of Advanced STS

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

ADVANCED PARKINSON'S DISEASE:

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Advancing Care Across the Spectrum of Pancreatic Cancer

Patient-Centered Management in Pancreatic Cancer

Personalizing Management in the Care of Patients With Advanced Sarcoma

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Program Goals Overview Is NEDA a Reasonable Target?

The Road to Quality Improvement in HER2-Positive Breast Cancer

When Is Intrathecal Drug Delivery Appropriate?

Treatment of Locally Advanced Pancreatic Cancer

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Management of Advanced Pancreatic Adenocarcinoma

Practical Guidance on the Management of Pan-Negative NSCLC

Incorporating Prostacyclins Into Practice

Challenges in LA SCCHN.

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

Clinical tips and pearls

Case Studies in Locally Advanced Pancreatic Cancer

When Is Intrathecal Drug Delivery Appropriate?

Prostacyclin Pathway Agents in Action

Early and locally advanced breast cancer

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Physiologic vs Chronologic Age

Physiologic vs Chronologic Age

Uncovering the Right Sequence

Presentation transcript:

Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

Case 1 78-Year-Old Man in Apparent Good Health

Case 1 Diagnosis and Staging

Case 1 Further Evaluation

Disease-Related Adverse Effects and Palliative Management

Disease-Related Adverse Effects and Palliative Management (cont)

Return to Case 1 Initial Treatment

Adverse Effects of FOLFIRINOX and Gemcitabine as First-Line Therapy

Management of Adverse Effects of FOLFIRINOX + Gemcitabine + XRT

Return to Case 1 Improvement With Chemotherapy Followed by Symptoms of Locally Advanced Disease

Treatment Options for Patients With Metastatic Pancreatic Adenocarcinoma

Nanoliposomal Irinotecan (MM-398) in Patients Who Failed to Respond to Gemcitabine

Treatment Options for Patients With Locally Advanced Metastatic Pancreatic Adenocarcinoma

Case 2 48-Year-Old Woman in Apparent Good Health

Case 2 Further Evaluation

Adverse Effects of nab-Paclitaxel + Gemcitabine Seen in the Clinical Trial

Comprehensive Care of Patients With Metastatic Disease

Open Communication With Patients

Strategies for Symptom Management and Maintaining Quality of Life

What Do You Tell Patients About Clinical Trials?

Summary

Abbreviations